14 Total results for product and free and sample content found
By Sue Darcey 18 Nov 2020
A few of the US Senate candidates favored and given tens of thousands of dollars by industry have lost their battles for re-election
By Cathy Kelly 18 Nov 2020
A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry
By Cathy Kelly 17 Nov 2020
Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.
By Joseph Haas 29 Oct 2020
EUA request for COVID-19 vaccine is unlikely before late November; the CEO’s frequent comments that the timetable isn’t politically motivated are unusual to say the least
By Sarah Karlin-Smith 21 Oct 2020
Company may have violated FDA’s preapproval promotion restrictions by discussing compassionate use option with Joe Biden’s team and by publicizing it on TV, highlighting the fine line between making the general public aware of expanded access and touting an investigational product as useful for a particular illness.
Pink Sheet, Scrip
By Sarah Karlin-Smith 09 Oct 2020
Trump receives Regeneron’s experimental antibody under FDA’s expanded access program, Gilead’s remdesivir and dexamethasone. The president’s treatment choices could influence clinical trials of all COVID-19 medicines and even trial recruitment for other diseases, experts said.
By Akriti Seth 25 Sep 2020
The AAM has published a timely guide highlighting various voter issues of concern in the run-up to the US elections, including anti-competitive tactics building on monopoly pricing and weak patent laws. The AAM has also called for policies to encourage generic and biosimilar entry in the market while the guide also focuses on policies around the US supply chain.
By Sarah Karlin-Smith 25 Sep 2020
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.
By Cathy Kelly 25 Sep 2020
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: